EpiEndo reports Phase 2A results for lead asset, EP395, in C

REYKJAVIK, Iceland, April 10, 2024--EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral, barrier-enhancing, anti-inflammatory therapeutics addressing chronic airway diseases, announces the successful completion of its Phase 2A clinical trial for EP395 in patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD).

Related Keywords

United Kingdom , Grosshansdorf , Schleswig Holstein , Germany , Reykjavik , C10 , Iceland , Geneva , Genè , Switzerland , Manchester , Ginny Norris , Maria Bech , Dave Singh , Henrik Watz , Epiendo Pharmaceuticals , University Of Manchester , World Economic Forum , Pulmonary Research Institute , Chronic Obstructive Pulmonary Disease , Principal Investigators , Professor Dave Singh , Respiratory Pharmacology , Medical Director , Medicines Evaluation Unit , Professor Henrik Watz , Lungen Clinic , Chief Medical Officer , Chief Executive Officer , Global Economic Burden , Endo Pharmaceuticals , Katie Duffell ,